CHECK1 (also known as CHEK1 or CHK1) encodes a serine/threonine-protein kinase that serves as a master regulator of the DNA damage checkpoint response. As the effector kinase of the ATR-CHK1 pathway, CHECK1 coordinates cell cycle arrest, DNA repair, and cell fate decisions in response to genotoxic stress. In post-mitotic neurons that are permanently arrested in G0, CHECK1 plays a distinct and critical role: it helps maintain genomic stability against the constant assault of oxidative damage, mitochondrial dysfunction, and environmental stressors that accumulate over decades of life[1].
The inappropriate re-activation of the cell cycle machinery—including CHECK1—in neurons is now recognized as a central feature of Alzheimer's disease and other neurodegenerative conditions. Neurons that attempt to re-enter the cell cycle face fatal outcomes, making CHECK1 both a biomarker of pathological stress and a potential therapeutic target[2].
| Property | Value |
|---|---|
| Gene Symbol | CHEK1 / CHECK1 |
| Protein Name | Checkpoint kinase 1 protein |
| Chromosomal Location | 11q24.2 |
| NCBI Gene ID | 1111 |
| UniProt ID | O14757 |
| Protein Length | 433 amino acids |
| Molecular Weight | ~54 kDa |
| Protein Class | Serine/Threonine protein kinase |
| Aliases | CHK1, Cdc2-like 1 (CLK1) |
| Expression | Ubiquitous; highest in brain, testis, thymus |
CHECK1 is a component of the DNA damage response (DDR) network that includes ATM, ATR, BRCA1, TP53, and the CDC25 phosphatase family. The protein consists of an N-terminal kinase domain and a C-terminal regulatory domain containing SQ/TQ cluster domains (SCDs) that serve as phosphorylation sites for ATM and ATR.
CHECK1 is primarily activated by the ATR kinase in response to replication stress and single-stranded DNA intermediates. Upon genotoxic insult, ATR phosphorylates CHECK1 at multiple sites—most critically at Ser317 and Ser345—triggering a conformational change that enables kinase activity[3]. Once activated, CHECK1 executes three principal functions:
Cell cycle arrest: CHECK1 phosphorylates CDC25A, targeting it for ubiquitin-mediated degradation. Loss of CDC25A prevents activation of CDK2-cyclin E, blocking G1/S transition[4].
DNA repair promotion: CHECK1 phosphorylates BRCA1, enhancing its recruitment to DNA damage sites and promoting homologous recombination repair[5].
Cell fate determination: CHECK1 phosphorylates p53 (TP53) at Ser15, stabilizing the tumor suppressor and activating transcription of pro-apoptotic genes when damage is irreparable[6].
In proliferating cells, CHECK1 stabilizes stalled replication forks by phosphorylating fork protection factors including CLASPIN and WRN[3:1]. This function is particularly relevant to neurons given their high metabolic activity and constant oxidative stress.
Emerging evidence shows CHECK1 phosphorylates transcription factors and chromatin modifiers in an activity-dependent manner, linking DNA damage signaling to gene expression programs involved in synaptic plasticity and neuronal survival[7].
In post-mitotic neurons, CHECK1 has evolved additional roles beyond cell cycle control:
Genomic integrity maintenance: Neurons accumulate thousands of DNA lesions daily from oxidative phosphorylation. CHECK1 coordinates repair pathways—base excision repair (BER), nucleotide excision repair (NER), and double-strand break repair—without triggering cell cycle re-entry[8].
Activity-dependent DNA damage response: Neural activity itself generates DNA double-strand breaks at enhancer regions, requiring CHECK1-mediated repair for proper gene regulation[9].
Mitochondrial genome maintenance: CHECK1 contributes to mtDNA repair and helps neurons cope with mitochondrial oxidative damage[10].
CHECK1 plays a dual role in Alzheimer's disease pathophysiology. On one hand, it represents a protective response to the widespread DNA damage observed in AD neurons. On the other hand, sustained CHECK1 activation drives pathological cell cycle re-entry[2:1].
DNA damage accumulation: AD brains show elevated levels of 8-oxoguanine lesions, single-strand breaks, and double-strand breaks in neurons. Oxidative stress from mitochondrial dysfunction, metal ion accumulation, and amyloid-beta toxicity all contribute to DNA damage that activates the ATR-CHECK1 pathway[11].
Cell cycle re-entry: Approximately 40-60% of neurons in AD hippocampus show markers of cell cycle re-entry, including cyclin E, CDK4, and phospho-RB. CHECK1 phosphorylation (Ser317) is detected in vulnerable neuronal populations before neurofibrillary tangle formation[12]. This paradoxical reactivation of the cell cycle—which neurons cannot complete—leads to apoptotic cell death[13].
Therapeutic implications: Paradoxically, both CHECK1 inhibition and CHECK1 activation may offer therapeutic benefit. Inhibition could prevent the pathological cell cycle re-entry, while activation could enhance DNA repair capacity. Current research suggests that moderate activation of the DDR, combined with cell cycle suppression, may be most beneficial[1:1].
Mitochondrial dysfunction and DNA damage: PD neurons, particularly dopaminergic neurons of the substantia nigra pars compacta, face chronic oxidative stress from mitochondrial complex I deficiency and alpha-synuclein aggregation. This oxidative damage activates the ATR-CHECK1 pathway[10:1].
PINK1-Parkin crosstalk: The PINK1-PARK2 mitophagy pathway, when defective in familial PD, leads to accumulation of damaged mitochondria and increased mtDNA mutations. CHECK1 may be activated by mtDNA damage and may cross-talk with PINK1 signaling pathways[14].
Dopaminergic neuron vulnerability: The high metabolic demands of dopaminergic neurons, combined with their pacemaking calcium influx, generate substantial oxidative DNA damage. CHECK1 helps coordinate repair, but chronic activation may contribute to neuronal dysfunction.
Transcription dysregulation and DNA damage: Mutant HTT causes transcriptional dysregulation, chromatin alterations, and accumulation of DNA damage. CHECK1 is chronically activated in HD models, contributing to both protective DNA repair and pathological signaling[15].
Selective striatal vulnerability: Medium spiny neurons (MSNs) of the striatum show particularly high sensitivity to DNA damage and cell cycle re-entry. CHECK1 may contribute to this selective vulnerability.
Therapeutic target: Modulating CHECK1 activity could reduce DNA damage-induced apoptosis in HD neurons while avoiding interference with essential DNA repair functions.
Oxidative DNA damage in motor neurons: ALS motor neurons accumulate oxidative DNA damage from superoxide dismutase mutations, TAR DNA-binding protein 43 (TDP-43) pathology, and excitotoxicity. CHECK1 activation is observed in ALS models and patient tissue[3:2].
RNA metabolism intersections: CHECK1 phosphorylates RNA processing factors, potentially linking DNA damage signaling to the RNA metabolism defects observed in ALS[4:1].
CHECK1 phosphorylates substrates at SQ/TQ consensus motifs. Key substrates in the neuronal context include:
| Substrate | Site | Function in Neurons |
|---|---|---|
| CDC25A | Ser123 | G1/S checkpoint |
| CDC25C | Ser216 | G2/M checkpoint |
| BRCA1 | Ser988 | DNA repair |
| TP53 | Ser15 | Apoptosis decision |
| CLASPIN | Ser756 | Replication fork protection |
| WRN | Ser227 | Fork restart |
| CREB1 | Ser133 | Transcriptional regulation |
| HDAC1 | Ser421 | Chromatin remodeling |
CHECK1 activity is negatively regulated by protein phosphatases PP1 and PP2A, which dephosphorylate the activation sites. These phosphatases are themselves regulated by DNA damage, creating a dynamic balance between CHECK1 activation and inactivation.
While ATR primarily activates CHECK1, ATM can also phosphorylate CHECK1 at Ser345 in response to double-strand breaks. The two kinases provide redundant but partially distinct activation of CHECK1, ensuring robust checkpoint signaling regardless of damage type[6:1].
CHK1 inhibitors have been extensively developed for cancer therapy, primarily to sensitize tumor cells to chemotherapy and radiation[16]. These inhibitors work by abrogating the G1/S and G2/M checkpoints, allowing cancer cells with unresolved DNA damage to proceed to mitotic catastrophe.
However, in the context of neurodegeneration, CHK1 inhibition is problematic because neurons depend on DNA repair capacity. Unchecked CHK1 inhibition in neurons could lead to catastrophic genomic instability. The therapeutic window would need careful evaluation.
Agents that mildly activate CHECK1 or enhance ATR-CHECK1 signaling could boost DNA repair in neurons. Such approaches might help neurons cope with the chronic DNA damage load in neurodegenerative disease[17]. However, over-activation risks driving pathological cell cycle re-entry.
Understanding the interaction between CHECK1 and other DNA repair genes could reveal selective vulnerabilities. For example, neurons with defective BER might depend more heavily on CHECK1-mediated checkpoint control.
Phospho-CHECK1 (Ser317) levels in cerebrospinal fluid or blood could serve as biomarkers of neuronal DNA damage burden, potentially useful for monitoring disease progression or treatment response.
CHECK1 operates within an extensive DNA damage response network:
Why do neurons with permanent cell cycle arrest maintain CHECK1? The persistence of CHECK1 in post-mitotic neurons suggests an evolutionary adaptation for DNA repair, not cell cycle control.
What triggers cell cycle re-entry specifically in AD? The link between CHECK1 activation and pathological cell cycle re-entry remains unclear; what differs from the protective DDR?
Can CHECK1 activity be modulated without impairing essential DNA repair? Therapeutic targeting requires understanding the threshold between protective and pathological CHECK1 activity.
How does CHECK1 interact with other neurodegeneration pathways? Its potential interactions with tau pathology, alpha-synuclein, and neuroinflammation are underexplored.
What is the role of CHECK1 in non-neuronal brain cells? Microglia, astrocytes, and oligodendrocytes also rely on DNA damage responses, and CHECK1 may play cell-type-specific roles.
Zhang X, et al. CHK1 in DNA damage response and neurodegeneration. Neurobiology of Aging. 2023. ↩︎ ↩︎
Iqbal K, et al. Neuronal cell cycle re-entry in Alzheimer disease. Nature Reviews Neuroscience. 2019. ↩︎ ↩︎
Chen L, et al. Global DNA damage response in neurodegenerative disorders. Molecular Neurobiology. 2023. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kim HJ, et al. Checkpoint kinase 1 in Alzheimer's disease. Journal of Alzheimer's Disease. 2022. ↩︎ ↩︎ ↩︎
Coppede F, et al. Genetics of DNA damage repair in neurodegeneration. Mutation Research. 2007. ↩︎ ↩︎
Konopka A, et al. Ataxia telangiectasia mutated in neurodegeneration. Trends in Neurosciences. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Maisterra-Haug J, et al. CHK1 regulates activity-dependent neuronal gene transcription. Journal of Neuroscience. 2018. ↩︎
Jiang Y, et al. DNA damage response in neurons and neurodegeneration. Cell Death and Differentiation. 2019. ↩︎ ↩︎
Madabhushi R, et al. Activity-induced DNA double-strand breaks drive neurodegeneration. Cell. 2014. ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegeneration. Nature Medicine. 2006. ↩︎ ↩︎
Krishnan V, et al. ATM and BER pathway defects in Alzheimer's disease. Journal of Neurochemistry. 2014. ↩︎
Andorfer C, et al. Cell cycle and tau pathology in Alzheimer's disease. Journal of Neuroscience. 2003. ↩︎
Khurana V, et al. A role for cell cycle re-entry in neurodegeneration. Biochimica et Biophysica Acta. 2006. ↩︎
Shirakura K, et al. PINK1-Parkin pathway and CHK1 in mitochondrial quality control. Scientific Reports. 2018. ↩︎
More J, et al. DNA repair in Huntington's disease pathogenesis. Brain Research. 2022. ↩︎
Plummer R, et al. CHK1 inhibitors in cancer therapy. Clinical Cancer Research. 2016. ↩︎
Rai R, et al. CHK1 signaling in neurodegeneration and aging. Aging Cell. 2018. ↩︎
Rai R, et al. Cell cycle checkpoint proteins in post-mitotic neurons. Cellular and Molecular Neurobiology. 2019. ↩︎